Haemodynamic Effects of Dobutamine in Patients with Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508298-10-00

Enrollment

Registered

2023-12-08

Start date

2024-04-01

Completion date

Unknown

Last updated

2023-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

Brief summary

Increase in cardiac output (CO) of 10 % and/or increase in stroke volume index (SVI) by ≥ 20%.

Detailed description

Reduction in mean pulmonary artery wedge pressure (PAWP) and/or mean pulmonary artery pressure (mPAP) by 10 %., Increase in left ventricular ejection fraction (LVEF) and left ventricular global longitudinal strain (LV-GLS) of absolute 10 %., Correlation between echo- and invasive measured stroke volume index (SVI), and cardiac output (CO)., Rate of complications/symptomatic side effects.

Interventions

DRUGGlukose Isotonisk "SAD"

DRUGinjektions- og infusionsvæske

DRUGopløsning

DRUGDobutrex

DRUGkoncentrat til infusionsvæske

DRUGNatriumklorid ”B. Braun”

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Increase in cardiac output (CO) of 10 % and/or increase in stroke volume index (SVI) by ≥ 20%.	—

Secondary

Measure	Time frame
Reduction in mean pulmonary artery wedge pressure (PAWP) and/or mean pulmonary artery pressure (mPAP) by 10 %., Increase in left ventricular ejection fraction (LVEF) and left ventricular global longitudinal strain (LV-GLS) of absolute 10 %., Correlation between echo- and invasive measured stroke volume index (SVI), and cardiac output (CO)., Rate of complications/symptomatic side effects.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026